CRISPR Therapeutics AG (NASDAQ:CRSP) Stock Holdings Reduced by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. lowered its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) by 5.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,746 shares of the company’s stock after selling 1,031 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in CRISPR Therapeutics were worth $762,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Arizona State Retirement System grew its stake in CRISPR Therapeutics by 4.6% in the fourth quarter. Arizona State Retirement System now owns 20,911 shares of the company’s stock valued at $850,000 after purchasing an additional 915 shares in the last quarter. Hollencrest Capital Management purchased a new position in CRISPR Therapeutics in the fourth quarter valued at about $25,000. Handelsbanken Fonder AB grew its stake in CRISPR Therapeutics by 27.6% in the fourth quarter. Handelsbanken Fonder AB now owns 12,500 shares of the company’s stock valued at $508,000 after purchasing an additional 2,700 shares in the last quarter. Envestnet Asset Management Inc. grew its stake in CRISPR Therapeutics by 12.1% in the fourth quarter. Envestnet Asset Management Inc. now owns 24,485 shares of the company’s stock valued at $995,000 after purchasing an additional 2,643 shares in the last quarter. Finally, TD Asset Management Inc boosted its stake in shares of CRISPR Therapeutics by 57.7% during the 4th quarter. TD Asset Management Inc now owns 181,827 shares of the company’s stock worth $7,391,000 after acquiring an additional 66,536 shares in the last quarter. Hedge funds and other institutional investors own 71.51% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on CRSP shares. Bryan, Garnier & Co started coverage on CRISPR Therapeutics in a research note on Friday, March 17th. They set a “buy” rating and a $70.00 price target for the company. Robert W. Baird started coverage on CRISPR Therapeutics in a research note on Monday, March 6th. They set a “neutral” rating and a $46.00 price target for the company. VNET Group reiterated a “reiterates” rating on shares of CRISPR Therapeutics in a research note on Tuesday. Citigroup decreased their price target on CRISPR Therapeutics from $63.00 to $55.00 in a research note on Friday, March 17th. Finally, JMP Securities restated a “market outperform” rating and set a $70.00 target price on shares of CRISPR Therapeutics in a research note on Monday, April 17th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $72.58.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 25,000 shares of the stock in a transaction that occurred on Wednesday, March 29th. The stock was sold at an average price of $44.46, for a total value of $1,111,500.00. Following the completion of the transaction, the chief executive officer now directly owns 387,377 shares of the company’s stock, valued at approximately $17,222,781.42. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last ninety days, insiders sold 75,000 shares of company stock valued at $3,584,500. Corporate insiders own 5.30% of the company’s stock.

CRISPR Therapeutics Stock Down 2.6 %

CRISPR Therapeutics stock opened at $66.01 on Friday. CRISPR Therapeutics AG has a 12 month low of $38.94 and a 12 month high of $86.95. The business has a 50 day moving average price of $48.62 and a two-hundred day moving average price of $49.94. The stock has a market cap of $5.21 billion, a price-to-earnings ratio of -9.82 and a beta of 1.71.

CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last issued its earnings results on Monday, May 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.64) by $0.97. CRISPR Therapeutics had a negative return on equity of 31.85% and a negative net margin of 54,271.70%. The business had revenue of $100.00 million during the quarter, compared to analysts’ expectations of $24.33 million. During the same period in the prior year, the firm posted ($2.32) EPS. CRISPR Therapeutics’s quarterly revenue was up 10538.3% compared to the same quarter last year. On average, analysts expect that CRISPR Therapeutics AG will post -7.22 earnings per share for the current fiscal year.

About CRISPR Therapeutics

(Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.